---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-123273"
form_type: "8-K"
ticker: "MNKD"
cik: "0000899460"
company_name: "MANNKIND CORP"
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T04:11:25.412640+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MannKind Q3 total revenue $70M (+37% YoY); YTD net income $20M, non-GAAP $45M

## Summary
- Q3 total revenue $70.1M (+37% YoY); YTD revenue $208.7M (+49% YoY); YTD net income $20M.
- Tyvaso DPI royalties up 34% to $27.1M (Q3) and 48% YTD to $75.3M; collaboration revenue +78% on manufacturing.
- Afrezza net revenue up 12% to $15.0M (Q3); V-Go net revenue up 5% to $4.7M.
- Pipeline: MNKD-101 Phase 3 global expansion; MNKD-201 Phase 1 complete, FDA meeting 1H 2025; INHALE-3 positive; pediatric data due Q4.
- Cash and investments $268.4M; $5.3M bargain purchase gain from Pulmatrix deal.

## SEC filing metadata
- accession: 0000950170-24-123273
- form_type: 8-K
- ticker: MNKD
- cik: 0000899460
- company_name: MANNKIND CORP
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899460/000095017024123273/0000950170-24-123273-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899460/000095017024123273/mnkd-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-123273
- JSON: https://secwatch.observer/filing/0000950170-24-123273.json
- Plain text: https://secwatch.observer/filing/0000950170-24-123273.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.